Washington, October 22
Kid-size doses of Pfizer’s Covid-19 vaccine appear safe and nearly 91 per cent effective at preventing symptomatic infections in five to 11-year-olds, according to study details released on Friday as the US considers opening vaccinations to that age group.
The shots could begin in early November — with the first children in line fully protected by Christmas — if regulators give the go-ahead.
Details of Pfizer’s study were posted online. The Food and Drug Administration was expected to post its independent review of the company’s safety and effectiveness data later. Advisers to the FDA will publicly debate the evidence next week. If the agency ultimately authorises the shots, the Centers for Disease Control and Prevention will make the final decision on who should receive them.
Full-strength Pfizer shots already are authorised for anyone 12 or older, but paediatricians and many parents are anxiously awaiting protection for younger children to stem rising infections from the extra-contagious delta variant and help keep kids in school. — AP
(The article is generated from The Tribune via feeds, The Chenab Times staff didn’t wrote this news.)
The Chenab Times News Desk